Advertisement

Search Results

Advertisement



Your search for all items matches 460 pages

Showing 301 - 350


skin cancer

Pembrolizumab Treatment May Cause Immune Cells to Express Markers of Reinvigoration

Treating patients with metastatic melanoma with the immunotherapy drug pembrolizumab (Keytruda) caused immune cells called CD8-positive T cells in the patient’s blood to express markers of reinvigoration, according to data being presented at the CRI-CIMT-EATI-AACR International Cancer...

issues in oncology
skin cancer

Frequency of Certain Immune Cells in Blood May Predict Response to Pembrolizumab in Metastatic Melanoma

Among patients with metastatic melanoma treated with the immunotherapy drug pembrolizumab (Keytruda), those whose cancer responded to the treatment had a higher frequency of T cells that were positive for the proteins CD8, PD-1, and Bim (CD8+PD-1+Bim+ T cells) in blood samples taken immediately...

skin cancer

Immune System–Boosting Agent May Reduce Early-Stage Melanoma Recurrences

Among patients with clinically stage I or stage II melanoma, those treated with the immune system–boosting agent CpG-B were less likely to experience recurrence of their disease than those who received placebo, according to results from two randomized, placebo-controlled phase II clinical...

skin cancer

BRAF V600 Mutation Appears to Be Targetable Oncogene in Some but Not All Nonmelanoma Cancers

In a phase II histology-independent basket study reported in The New England Journal of Medicine, Hyman et al found that the BRAF V600 kinase inhibitor vemurafenib (Zelboraf) exhibited activity in some but not all nonmelanoma cancers with BRAF V600 mutations. Study Details In the study, 122...

skin cancer
issues in oncology

Patients With Fewer Than 50 Moles May Be at Risk for More Aggressive Melanoma

People with more than 50 moles have an increased risk of developing melanoma, but those with fewer than 50 moles should still be alert for this disease. In fact, according to new research presented at the American Academy of Dermatology’s 2015 Summer Academy Meeting in New York, those with...

skin cancer

Pembrolizumab Cutaneous Adverse Events May Predict Better Response

In a single-center retrospective review reported in JAMA Dermatology, Sanlorenzo et al found that cutaneous adverse events in patients receiving the anti–PD-1 agent pembrolizumab (Keytruda), currently approved for treatment of melanoma, may indicate better treatment response. Study Details...

skin cancer

Organ Transplant Recipients May Be More Likely to Develop Aggressive Melanoma

Organ transplant recipients are twice as likely to develop melanoma as people who do not undergo a transplant and three times more likely to die of the skin cancer, suggested new research by a multi-institutional team. The findings, reported by Robbins et al in the Journal of Investigative...

palliative care
skin cancer

Combining Interleukin-2 With Imiquimod and Topical Retinoid Therapy May Be Effective Against Cutaneous Metastatic Melanoma

A novel combination therapy appears to be effective in treating patients with melanoma skin metastases, according to new research from the University of California (UC) Davis. Led by Emanual Maverakis, MD, of the UC Davis Department of Dermatology, the research found that interleukin-2...

lymphoma
skin cancer
lymphoma

Identification of Risk Factors for Melanoma in Survivors of Non-Hodgkin Lymphoma

Risk for melanoma has been found to be increased in non-Hodgkin lymphoma (NHL) survivors. In a study reported in the Journal of Clinical Oncology, Lam et al found that T-cell–activating autoimmune diseases and fludarabine use were associated with an increased melanoma risk among patients with ...

skin cancer
skin cancer

Annual Incidence of Melanoma Projected to Increase Markedly by 2030

As reported in Morbidity and Mortality Weekly Report by Guy et al, data from the Centers for Disease Control and Prevention (CDC) indicate that there were an estimated 65,647 new cases of invasive melanoma in the United States in 2011. In the absence of intervention, the annual incidence is...

skin cancer
skin cancer
issues in oncology

Key Genetic Factor in Cell Proliferation in Moles Identified

Scientists have known for years that a mutation in the BRAF gene makes moles start to grow but until now have not understood why they sometimes do not become cancerous. Researchers from the Perelman School of Medicine at the University of Pennsylvania have identified a major genetic factor that...

skin cancer

Reduced Relapse but No Overall Survival Benefit With Adjuvant Lymph-Node Field Radiotherapy in High-Risk Melanoma

The 6-year follow-up of the phase III ANZMTG 01.02/TROG 02.01 trial, reported in The Lancet Oncology by Henderson et al, showed that adjuvant lymph-node field radiotherapy in melanoma patients with high risk of lymph-node field recurrence reduced the rate of recurrence but did not improve overall...

skin cancer

FDA Approves Sonidegib for Locally Advanced Basal Cell Carcinoma

The U.S. Food and Drug Administration (FDA) approved sonidegib (Odomzo) for the treatment of patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy or those who are not candidates for surgery or radiation therapy. The approval was based on...

skin cancer

Low Incidence of Infusion-Related Reactions Reported With 30-Minute Ipilimumab Infusion

In a single-institution study reported in the Journal of Clinical Oncology, Momtaz et al found that the rate of infusion-related reactions remained acceptably low when ipilimumab (Yervoy) 3 mg/kg was infused over 30 minutes in patients with advanced melanoma. The currently approved dose of...

skin cancer

Adverse Event Reporting System Indicates Renal Toxic Effects With BRAF Inhibitors Vemurafenib and Dabrafenib

In an analysis of FDA Adverse Event Reporting System data reported in JAMA Oncology, Jhaveri et al found that the BRAF inhibitors vemurafenib (Zelboraf) and dabrafenib (Tafinlar) were associated with nephrotoxicity. Their findings suggest a need to monitor renal function and electrolyte levels ...

cns cancers
gynecologic cancers
colorectal cancer
leukemia
lymphoma
skin cancer
gynecologic cancers
issues in oncology
issues in oncology
issues in oncology

Noninvasive Prenatal Testing May Also Detect Some Maternal Cancers

A study published by Bianchi et al in the Journal of the American Medical Association (JAMA) showed that genetic test results revealed by noninvasive prenatal testing for fetal chromosomal abnormalities may detect underlying conditions in the mother, including cancer. The study reports on a case...

skin cancer

Pembrolizumab Increases Progression-Free Survival vs Chemotherapy in Ipilimumab-Refractory Advanced Melanoma

In the randomized phase II KEYNOTE-002 trial reported in The Lancet Oncology, Ribas et al found that treatment with the anti–PD-1 antibody pembrolizumab (Keytruda) prolonged progression-free survival vs investigator-choice chemotherapy in patients with advanced melanoma progressing on...

skin cancer

Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction Associated With Risk of Melanoma

In a study in Swedish men reported in JAMA, Loeb et al found a statistically significant increase in risk of malignant melanoma in those using oral phosphodiesterase type 5 (PDE5) inhibitors for erectile dysfunction. However, risk was not significantly elevated in men filling multiple PDE5...

issues in oncology
skin cancer
issues in oncology

Mapping Genetic Mutations in Cutaneous Melanoma

Researchers have a significantly better understanding of the genetic alterations found in cutaneous melanoma as part of a multi-institution, international effort of The Cancer Genome Atlas (TCGA). The study, published in Cell, refined and revealed new molecular subgroups of patients who could...

skin cancer

Citrus Fruit Consumption May Be Linked to An Increased Risk of Melanoma

A large population-based prospective analysis of the consumption of psoralen-rich citrus products and the risk of malignant melanoma has found that the melanoma risk was 36% higher in people who consumed citrus fruit or juice at least 1.6 times daily compared with those who consumed it less than...

skin cancer

Dabrafenib Plus Trametinib Improves Overall Survival vs Dabrafenib in BRAF V600–Mutant Melanoma

Overall survival results of a phase III COMBI-d trial reported in The Lancet by Long et al showed that the combination of the BRAF inhibitor dabrafenib (Tafinlar) with the MEK inhibitor trametinib (Mekinist) resulted in significantly prolonged overall survival vs dabrafenib alone in patients with...

palliative care
issues in oncology
skin cancer
issues in oncology

Pooled Analysis Shows Similar Efficacy of Nivolumab in BRAF V600–Mutant and BRAF Wild-Type Advanced Melanoma

A pooled analysis of four clinical trials of nivolumab (Opdivo) in advanced melanoma, reported by Larkin et al in JAMA Oncology, suggested similar response rates in patients with BRAF V600–mutant and BRAF wild-type disease. Study Details The retrospective analysis included data from adult...

skin cancer

Oncolytic Immunotherapy With Talimogene Laherparepvec Improves Durable Response Rate in Advanced Melanoma

In a phase III trial reported in the Journal of Clinical Oncology, Andtbacka et al found that talimogene laherparepvec (T-VEC) treatment improved the durable response rate vs granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with unresectable stage IIIB to IV melanoma. T-VEC is...

skin cancer

ASCO 2015: Complete Lymph Node Dissection Does Not Improve Survival in Patients With Melanoma and Micrometastases

For patients with melanoma and micrometastases, as shown by positive sentinel lymph node biopsy, complete lymph node dissection did not improve survival, according to results of a randomized study presented at the 2015 ASCO Annual Meeting (Abstract LBA9002). “This is the first study which...

skin cancer

ASCO 2015: Phase III Study Finds Nivolumab Improves Progression-Free Survival, Especially When Combined With Ipilimumab, in Advanced Melanoma

A randomized phase III trial among patients with previously untreated melanoma found that initial therapy with nivolumab (Opdivo) alone more than doubled the median progression-free survival compared with ipilimumab (Yervoy) alone (6.9 vs 2.9 months), and the benefit was even greater when the two...

skin cancer

ASCO 2015: Melanoma Rates Dramatically Increasing in Children and Young Adults

The incidence of melanoma has increased by more than 250% among children, adolescents, and young adults since 1973, according to research to be presented by Roswell Park Cancer Institute (RPCI) on June 1 at the 2015 ASCO Annual Meeting (Abstract 9058) in Chicago. The research has been recognized...

skin cancer

Vismodegib Safety Profile in Long-Term ‘Real-World’ Use in Advanced Basal Cell Carcinoma

In a preplanned interim analysis of the international open-label STEVIE trial reported in The Lancet Oncology, Basset-Seguin et al have provided safety data and efficacy outcomes with the use of vismodegib (Erivedge) for 1 year in patients with advanced basal cell carcinoma. STEVIE was designed to...

skin cancer

Hedgehog Inhibitor Sonidegib Active in Advanced Basal Cell Carcinoma

In the phase II BOLT trial reported in The Lancet Oncology, Migden et al found that the hedgehog pathway signaling inhibitor sonidegib produced responses in patients with locally advanced or metastatic basal cell carcinoma at 200-mg and 800-mg dose levels. The lower dose appeared to be associated...

skin cancer
skin cancer
issues in oncology

Patients’ Desire for Rapid Notification of Skin Biopsy Results Leads to Preference for Phone Call Over In-Person Discussion

Patients’ preference for how they receive biopsy results “has shifted from face-to-face visit to discussion over the telephone because of a desire for rapid notification,” according to a survey of 301 patients recruited at three different melanoma clinics. A total of 67.1% of the...

skin cancer

Poorer Melanoma-Specific Survival With Stage ≥ T2b Tumors With NRAS or BRAF Mutation

In a population-based study reported in JAMA Oncology, Thomas and colleagues found significantly poorer disease-specific survival among melanoma patients with stage ≥ T2b tumors with NRAS or BRAF mutation. Study Details The study included data from 912 U.S. or Australian patients in the...

skin cancer
issues in oncology

ASCO 2015: Oral Vitamin Reduces Risk of Common Nonmelanoma Skin Cancers in High-Risk Patients

The Australian ONTRAC trial showed that a form of vitamin B3 called nicotinamide significantly reduced the rates of new skin cancers in people at high risk of the disease. Taken as a twice-daily pill, nicotinamide reduced the incidence of new nonmelanoma skin cancers by 23%. These findings were...

skin cancer

Anti–PD-1 Antibody Pembrolizumab Improves Progression-Free and Overall Survival vs Ipilimumab in Advanced Melanoma

In the phase III KEYNOTE-006 trial reported in The New England Journal of Medicine, Robert et al found that the anti–PD-1 antibody pembrolizumab (Keytruda) increased progression-free and overall survival compared with ipilimumab in patients with advanced melanoma. Study Details In this...

skin cancer

Addition of Nivolumab to Ipilimumab Improves Response Rate and Progression-Free Survival in Previously Untreated Advanced Melanoma

In a phase II study reported in The New England Journal of Medicine, Postow et al found that dual checkpoint inhibitor therapy with the anti–CTLA-4 antibody ipilimumab (Yervoy) and the anti–PD-1 monoclonal antibody nivolumab (Opdivo) produced greater response rates and prolonged...

skin cancer

FDA Accepts Supplemental Biologics License Application for Nivolumab in Patients With Previously Untreated Advanced Melanoma

The U.S. Food and Drug Administration (FDA) has accepted for filing and review Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for nivolumab (Opdivo) for the treatment of previously untreated patients with unresectable or metastatic melanoma. The FDA also granted...

palliative care
skin cancer

AACR 2015: Combining Two Investigational Immunotherapy Drugs Safe, With Early Signs of Effectiveness

Combining the immunostimulatory anti-CD40 monoclonal antibody CP-870,893 with the immune checkpoint inhibitor tremelimumab was found to be safe, with clinical evidence of response in patients with advanced melanoma, according to phase I clinical trial data presented at the AACR Annual Meeting 2015, ...

palliative care
skin cancer

AACR 2015: Improved Responses With Ipilimumab-Nivolumab Combination vs Ipilimumab Alone in Advanced Melanoma

Giving the two immunotherapies ipilimumab (Yervoy) and nivolumab (Opdivo) simultaneously yielded better treatment responses than ipilimumab alone in patients with advanced melanoma who received no prior treatment, according to phase II clinical trial data presented at the AACR Annual Meeting 2015,...

skin cancer

AACR 2015: New Immunotherapy Yields Long-Lasting Responses in Some Patients With Advanced Melanoma

A first-in-class immunotherapy called IMCgp100 yielded durable responses in patients with advanced cutaneous melanoma and those with advanced ocular melanoma, according to data from a phase I/IIa clinical trial presented at the AACR Annual Meeting 2015, held April 18 to 22 in Philadelphia (Abstract ...

skin cancer

Microscopic Melanoma Metastases in Less Radioactive Sentinel Lymph Nodes Pose Risk of Progression and Mortality

In a study reported in JAMA Surgery, Luo et al found that microscopic melanoma metastases in sentinel lymph nodes that were not the most radioactive (“hottest”) were still associated with an increased risk of progression and mortality. The study involved data from 475 consecutive...

skin cancer

AACR 2015: Pembrolizumab Is Better Than Ipilimumab for Advanced Melanoma in Phase III Trial

In the first randomized trial to compare two U.S. Food and Drug Administration–approved immune checkpoint inhibitors as first-line therapy for patients with advanced melanoma, pembrolizumab (Keytruda) yielded significantly better treatment outcomes than ipilimumab (Yervoy) for all endpoints...

skin cancer

One in Five Medicare Patients With Melanoma Experience Surgical Delays

A large retrospective cohort study of more than 32,000 Medicare beneficiaries diagnosed with melanoma has found that one in five patients experience a delay of surgery that is longer than 1.5 months. Those patients undergoing biopsy and surgery by dermatologists had the lowest risk for delay, which ...

skin cancer

Adjuvant Ipilimumab Increases Recurrence-Free Survival vs Placebo After Complete Resection of High-Risk Stage III Melanoma

In the phase III EORTC 18071 trial reported in The Lancet Oncology, Eggermont et al found that adjuvant ipilimumab (Yervoy) significantly improved recurrence-free survival vs placebo in patients with completely resected stage III melanoma at high risk of disease recurrence. Ipilimumab was...

skin cancer

Five-Year Analysis Indicates Potential for Long‑Term Survival With Ipilimumab Plus Dacarbazine in Advanced Melanoma

In an analysis reported in the Journal of Clinical Oncology, Maio et al found a 5-year survival rate of 18% among treatment-naive patients receiving ipilimumab (Yervoy) plus dacarbazine in a phase III trial. The findings support other data indicating long-term survival in some patients receiving...

skin cancer

Nivolumab Increases Response Rate vs Chemotherapy in Advanced Melanoma With Progression After Anti–CTLA-4 Treatment

In the phase III CheckMate 037 trial reported in The Lancet Oncology, Weber et al found that treatment with the PD-1 inhibitor nivolumab (Opdivo) resulted in a significantly greater response rate vs chemotherapy as second- or later-line treatment in patients with advanced melanoma progressing after ...

skin cancer

Elevated C-Reactive Protein Associated With Poorer Outcome in Melanoma

In a study reported in the Journal of Clinical Oncology, Fang et al found that an elevated C-reactive protein level was associated with poorer overall and melanoma-specific survival in patients with melanoma and that sequential increases in C-reactive protein were associated with an increased risk...

skin cancer

Findings in Pooled Analysis of Long-Term Survival With Ipilimumab in Advanced Melanoma

In a pooled analysis reported in the Journal of Clinical Oncology, Schadendorf et al found 3-year overall survival rates of 26% and 20% in treatment-naive and previously treated patients receiving ipilimumab (Yervoy)-based treatment for unresectable or metastatic melanoma. A survival curve plateau...

skin cancer

BRAF Wild-Type Melanomas During Dabrafenib Treatment for Metastatic BRAF V600E Melanoma

In a case report in JAMA Dermatology, Carrera et al described development of multiple wild-type BRAF melanomas and a metastasis with a different BRAF mutation in a patient receiving dabrafenib (Tafinlar) for BRAF V600E–mutant metastatic melanoma. Development of Melanomas As described...

skin cancer
issues in oncology

NRAS Mutations in Advanced Melanoma Correlate With Increased Benefit From Immunotherapies

Researchers investigating whether tumor genotype correlates with benefit from immune therapy in melanoma has found that patients whose tumors had NRAS mutations had better response to immunotherapy and better outcomes than patients whose tumors had other genetic subtypes. The results suggest that...

skin cancer
issues in oncology
issues in oncology

Study Shows Lack of RNA Editing Leads to Melanoma Growth and Metastasis

In a new study reported by Shoshan et al in Nature Cell Biology, researchers at The University of Texas MD Anderson Cancer Center established a link between melanoma and lack of RNA editing, which leads to tumor growth and progression through manipulation of proteins. Study Findings Study lead...

skin cancer

FDA Grants Cobimetinib Priority Review for Use in Combination With Vemurafenib in Advanced Melanoma

The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for Genentech’s New Drug Application (NDA) for cobimetinib in combination with vemurafenib (Zelboraf) for the treatment of people with BRAF V600 mutation–positive advanced melanoma. The FDA will make a...

skin cancer

Vitiligo Predicts Improved Survival in Patients Receiving Immunotherapy for Stage III or IV Melanoma

In a systematic review and meta-analysis reported in the Journal of Clinical Oncology, Teulings et al found that development of vitiligo in patients receiving immunotherapy for stage III or IV melanoma was a significant predictor of improved progression-free and overall survival. The study...

Advertisement

Advertisement



Advertisement